Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ) is now available.
JCR Pharmaceuticals and Modalis Therapeutics have advanced their joint research agreement to the next phase, focusing on the development of a novel gene therapy for a central nervous system disease. This collaboration leverages JCR’s J-Brain Cargo® technology and Modalis’ CRISPR-GNDM® platform to enhance drug delivery and gene modulation, aiming for improved efficacy and safety in treatment. The announcement signifies a strategic step that could potentially impact the field of CNS diseases through innovative therapeutic possibilities, although it is expected to have a minor financial impact on both companies this fiscal year.
More about JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceuticals company focused on advancing treatments for rare and genetic diseases, including conditions such as growth disorder, MPS II, Fabry disease, acute graft-versus-host disease, and renal anemia. Modalis Therapeutics Corporation, founded in 2016, is a pioneer in epigenetic medicine, developing therapeutics for serious genetic disorders like neuromuscular diseases, CNS diseases, and cardiomyopathies using its proprietary CRISPR-GNDM® technology.
YTD Price Performance: 0%
Average Trading Volume: 365,374
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: Yen75.12B
See more insights into 4552 stock on TipRanks’ Stock Analysis page.